PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1570
- Registration Number
- NCT00640042
Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Biological: PlaceboBiological: PF-04603629
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2009-07-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT00638313
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, San Antonio, Texas, United States
A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury
Phase 4
Terminated
- Conditions
- Brain InjuriesGrowth Hormone Deficiency Dwarfism
- Interventions
- Genetic: somatropin
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00638053
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Federal Way, Washington, United States
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT00637780
- Locations
- ๐ฒ๐ฝ
Private Office, Guadalajara, Jalisco, Mexico
๐บ๐ธUniversity Hospitals Case Medical Center, Cleveland, Ohio, United States
A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaAdvanced MDS
- Interventions
- Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00637052
- Locations
- ๐บ๐ธ
Emory University School of Medicine, Winship Cancer Center, Atlanta, Georgia, United States
๐บ๐ธUniversity of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus
Phase 1
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Biological: PF-04603629Biological: Placebo
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2009-07-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00637338
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Portland, Oregon, United States
A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery
Phase 3
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2008-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1671
- Registration Number
- NCT00636064
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Oxford, United Kingdom
Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis
Phase 2
Terminated
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2013-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 222
- Registration Number
- NCT00634933
- Locations
- ๐ท๐ธ
Pfizer Investigational Site, Niska Banja, Serbia
CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
Phase 1
Withdrawn
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00635245
A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00635401
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Oita, Japan
ยฉ Copyright 2025. All Rights Reserved by MedPath